BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Sookoian S, Pirola CJ. Repurposing drugs to target nonalcoholic steatohepatitis. World J Gastroenterol 2019; 25(15): 1783-1796 [PMID: 31057294 DOI: 10.3748/wjg.v25.i15.1783]
URL: https://www.wjgnet.com/1007-9327/full/v25/i15/1783.htm
Number Citing Articles
1
Marta Iruarrizaga-Lejarreta, Enara Arretxe, Cristina Alonso. Using metabolomics to develop precision medicine strategies to treat nonalcoholic steatohepatitisExpert Review of Precision Medicine and Drug Development 2019; 4(5): 283 doi: 10.1080/23808993.2019.1685379
2
Carlos J. Pirola, Silvia Sookoian. The lipidome in nonalcoholic fatty liver disease: actionable targetsJournal of Lipid Research 2021; 62: 100073 doi: 10.1016/j.jlr.2021.100073
3
Ga-Ram Yu, Seung-Jun Lee, Dong-Woo Lim, Hyuck Kim, Jai-Eun Kim, Won-Hwan Park. Drug Repurposing in Alternative Medicine: Sochehwan, a Polyherbal Traditional Korean Digestant, Protects against Alcoholic Steatohepatitis by Regulating Cytochrome P450 2E1 ExpressionProcesses 2021; 9(10): 1760 doi: 10.3390/pr9101760
4
Danae Stella Zareifi, Odysseas Chaliotis, Nafsika Chala, Nikos Meimetis, Maria Sofotasiou, Konstantinos Zeakis, Eirini Pantiora, Antonis Vezakis, George K. Matsopoulos, Georgios Fragulidis, Leonidas G. Alexopoulos. A network-based computational and experimental framework for repurposing compounds toward the treatment of non-alcoholic fatty liver diseaseiScience 2022; 25(3): 103890 doi: 10.1016/j.isci.2022.103890
5
Silvia Sookoian, Carlos J. Pirola. Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune responseClinical and Molecular Hepatology 2023; 29(Suppl): S184 doi: 10.3350/cmh.2022.0318
6
Castillo Tomas Augusto, María de la Paz Scribano Parada, Micaela Milagros Rossi, Franco Signorini, Ismael Fonseca, María del Carmen Baez. Pharmacological Action of Atorvastatin and Metformin on Non-alcoholic Fatty Liver Disease on an Experimental Model of Metabolic SyndromeAnti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2021; 21(3): 194 doi: 10.2174/1871523022666230223090714
7
Cyriac Abby Philips, Guruprasad Padsalgi, Rizwan Ahamed, Rajaguru Paramaguru, Sasidharan Rajesh, Tom George, Pushpa Mahadevan, Philip Augustine. Repurposing Pirfenidone for Nonalcoholic Steatohepatitis-related Cirrhosis: A Case SeriesJournal of Clinical and Translational Hepatology 2020; 8(X): 1 doi: 10.14218/JCTH.2019.00056
8
Silvia Sookoian, Carlos J. Pirola. Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biologyClinical and Molecular Hepatology 2020; 26(4): 461 doi: 10.3350/cmh.2020.0136
9
Wan-Yu Yang, Pei-Shu Rao, Yong-Chun Luo, Hua-Kuo Lin, Sing-Han Huang, Jinn-Moon Yang, Chiou-Hwa Yuh. Omics-based Investigation of Diet-induced Obesity Synergized with HBx, Src, and p53 Mutation Accelerating Hepatocarcinogenesis in Zebrafish ModelCancers 2019; 11(12): 1899 doi: 10.3390/cancers11121899
10
Hua Zhang, Yongyuan Ma, Xinying Cheng, Dongbo Wu, Xingming Huang, Bin Chen, Yafeng Ren, Wei Jiang, Xiaoqiang Tang, Ting Bai, Yutian Chen, Yilin Zhao, Chunxue Zhang, Xia Xiao, Jing Liu, Yue Deng, Tinghong Ye, Lu Chen, Han-Min Liu, Scott L. Friedman, Liping Chen, Bi-Sen Ding, Zhongwei Cao. Targeting epigenetically maladapted vascular niche alleviates liver fibrosis in nonalcoholic steatohepatitisScience Translational Medicine 2021; 13(614) doi: 10.1126/scitranslmed.abd1206
11
Alessandro Federico, Marcello Dallio, Mario Masarone, Antonietta Gerarda Gravina, Rosa Di Sarno, Concetta Tuccillo, Valentina Cossiga, Stefania Lama, Paola Stiuso, Filomena Morisco, Marcello Persico, Carmelina Loguercio. Evaluation of the Effect Derived from Silybin with Vitamin D and Vitamin E Administration on Clinical, Metabolic, Endothelial Dysfunction, Oxidative Stress Parameters, and Serological Worsening Markers in Nonalcoholic Fatty Liver Disease PatientsOxidative Medicine and Cellular Longevity 2019; 2019: 1 doi: 10.1155/2019/8742075
12
Manush Saydmohammed, Anupma Jha, Vineet Mahajan, Dillon Gavlock, Tong Ying Shun, Richard DeBiasio, Daniel Lefever, Xiang Li, Celeste Reese, Erin E Kershaw, Vijay Yechoor, Jaideep Behari, Alejandro Soto-Gutierrez, Larry Vernetti, Andrew Stern, Albert Gough, Mark T Miedel, D Lansing Taylor. Quantifying the progression of non-alcoholic fatty liver disease in human biomimetic liver microphysiology systems with fluorescent protein biosensorsExperimental Biology and Medicine 2021; 246(22): 2420 doi: 10.1177/15353702211009228
13
Nasim Bakhtiyari, Sepideh Parvizpour, Yosef Masoudi-Sobhanzadeh, Ali Masoudi-Nejad. Computational-based strategies to deal with liver injuries induced by the repurposed drugs against SARS-CoV-2Informatics in Medicine Unlocked 2023; 41: 101336 doi: 10.1016/j.imu.2023.101336
14
Paolo Caraceni, Juan G. Abraldes, Pere Ginès, Phil N. Newsome, Shiv K. Sarin. The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discoveryJournal of Hepatology 2021; 75: S118 doi: 10.1016/j.jhep.2021.01.024
15
Carlos J. Pirola, Silvia Sookoian. Repurposing drugs to target nonalcoholic steatohepatitis: Auranofin, a gold-organic molecule complex for the treatment of a specifc complex traitClinical and Molecular Hepatology 2022; 28(4): 806 doi: 10.3350/cmh.2022.0208